menu
    • menu

    Company profile for Dermavant Sciences

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. Dermavant leverages the Roivant platform to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dermavant SciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3780 Kilroy Airport Way Suite 250 Long Beach, CA 90806
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dermavant.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dermavant-sciences/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/dermavant

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dermavant Sciences`s Nduvra Receives Approval in Canada
    Dermavant Sciences`s Nduvra Receives Approval in Canada

    04 Apr 2025

    // HEALTH CANADA

    https://pdf.hres.ca/dpd_pm/00080148.PDF

    HEALTH CANADA
    04 Apr 2025
    Share Share
    Dermavant Presents VTAMA® Data for Atopic Dermatitis at Conference
    Dermavant Presents VTAMA® Data for Atopic Dermatitis at Conference

    25 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241025130494/en

    BUSINESSWIRE
    25 Oct 2024
    Share Share
    Dermavant Presents On Itch & Sleep Improves In Atopic Dermatitis
    Dermavant Presents On Itch & Sleep Improves In Atopic Dermatitis

    24 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241024840833/en

    BUSINESSWIRE
    24 Oct 2024
    Share Share
    Organon pays up to $1.2B to acquire Dermavant and its steroid-free cream Vtama
    Organon pays up to $1.2B to acquire Dermavant and its steroid-free cream Vtama

    19 Sep 2024

    // REUTERS

    https://www.reuters.com/markets/deals/organon-buy-therapy-developer-dermavant-up-12-billion-2024-09-18/

    REUTERS
    19 Sep 2024
    Share Share
    Dermavant announces approval of Tapinarof for psoriasis and atopic dermatitis
    Dermavant announces approval of Tapinarof for psoriasis and atopic dermatitis

    25 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240625865698/en

    BUSINESSWIRE
    25 Jun 2024
    Share Share
    Dermavant VTAMA Atopic Dermatitis Data Published In JAAD
    Dermavant VTAMA Atopic Dermatitis Data Published In JAAD

    21 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240521232125/en

    BUSINESSWIRE
    21 May 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search